PODD Stock Summary and Trading Ideas (Insulet | NASDAQ:PODD)

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.

Insulet trades on the NASDAQ stock market under the symbol PODD.

As of August 14, 2026, PODD stock price declined to $143.34 with 738,570 million shares trading.

PODD has a beta of -0.31, meaning it tends to be less sensitive to market movements. PODD has a correlation of 0.01 to the broad based SPY ETF.

PODD has a market cap of $10.09 billion. This is considered a Large Cap stock.

Last quarter Insulet reported $802 million in Revenue and $1.66 earnings per share. This beat revenue expectation by $14 million and exceeded earnings estimates by $.22.

In the last 3 years, PODD traded as high as $354.88 and as low as $125.82.

The top ETF exchange traded funds that PODD belongs to (by Net Assets): VTI, VOO, VB, RSP, VBK.

PODD has underperformed the market in the last year with a price return of -53.6% while the SPY ETF gained +21.5%. PODD has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -3.7% and -13.5%, respectively, while the SPY returned +4.0% and +3.9%, respectively.

PODD support price is $142.63 and resistance is $150.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PODD shares will trade within this expected range on the day.